Table 4.
Mortality for COVID-19 pneumonia: estimated outcome predictors based on statistical analysis with Fisher’s exact test
| Parameter | Comparison | p-value |
|---|---|---|
| Gender | Female versus male | 0.459 |
| Age | ≤ 65 versus other | 0.699 |
| ≤ 75 versus other | 0.423 | |
| ISS stage | I + II versus III | 1.000 |
| ECOG (performance status) | 0–2 versus ≥ 3 | 0.001 |
| Comorbidities | 0–1 versus ≥ 2 | 0.007 |
| Treatment line | 1–2 versus ≥ 3 | 1.000 |
| MM treatment response | Responsive versus active disease | 0.692 |
| Type of last MM treatment | Daratumumab-based versus other | 1.000 |
| Lenalidomide-based versus other | 1.000 | |
| Bortezomib-based versus other | 0.467 | |
| Hospitalization unit type | standard versus intensive care unit | 0.001 |
| Type of COVID-19 treatment | Remdesivir + convalescent plasma versus other | 1.000 |
| Immunoparesis | Yes versus no | 0.258 |